Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01177228
First received: August 5, 2010
Last updated: June 19, 2014
Last verified: June 2014
  Purpose

The main objectives of this study were to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of vedolizumab in patients with ulcerative colitis (UC).


Condition Intervention Phase
Ulcerative Colitis
Drug: Vedolizumab
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN0002 Following Multiple Intravenous Doses in Patients With Ulcerative Colitis

Resource links provided by NLM:


Further study details as provided by Millennium Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Number of Participants With Adverse Events [ Time Frame: From the first date of study drug administration through Day 253 ] [ Designated as safety issue: Yes ]

    An adverse event (AE) is any untoward medical occurrence in a patient administered a pharmaceutical product, which does not necessarily have a causal relationship with the treatment. The investigator systematically collected information adequate to determine both the outcome and severity of the AE, and whether or not it was drug-related or met the criteria for classification as a serious adverse event (SAE). An SAE was defined as an AE that resulted in (or posed risk for) death, inpatient hospitalization (or prolonging hospitalization), or congenital, persistent or significant disability/incapacity.

    The intensity for each AE was defined according to the following criteria:

    Mild: Awareness of sign or symptom, but easily tolerated Moderate: Discomfort enough to cause interference with normal daily activities Severe: Inability to perform normal daily activities.


  • Cmax: Maximum Observed Plasma Concentration of Vedolizumab on Days 1 and 85 [ Time Frame: Days 1 and 85, prior to and 2, 12, 24, 48, and 72 hours after dosing. ] [ Designated as safety issue: No ]
    Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

  • Cmin: Minimum Observed Plasma Concentration of Vedolizumab [ Time Frame: Day 85, prior to and 2, 12, 24, 48, and 72 hours after dosing. ] [ Designated as safety issue: No ]
    Minimum observed plasma concentration (Cmin) is the lowest plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

  • Area Under the Plasma Concentration-Time Curve (AUC) for Vedolizumab [ Time Frame: Days 0-14, Days 85-99, Days 85-141 ] [ Designated as safety issue: No ]

    AUC was calculated for 3 time intervals during the study:

    1. AUC (Day 0-14): from administration on Day 0 to last quantifiable concentration on Day 14, selected to capture the AUC following the first dose of vedolizumab until administration of the second dose
    2. AUC(Day 85-99): from administration on Day 85 to last quantifiable concentration on Day 99, selected to assess the amount of drug accumulation with the planned loading regimen by comparing it to AUC(Day 0-14)
    3. AUC(Day 85-141): from the first quantifiable concentration on Day 85 to the last quantifiable concentration on Day 141, selected to assess the drug exposure over an 8-week period

  • Terminal Phase Elimination Half-life (t½) of Vedolizumab [ Time Frame: Pre-dose through Day 253 ] [ Designated as safety issue: No ]
    Terminal phase elimination half-life (t½) is the time required for half of the drug to be eliminated from the plasma.

  • Maximum Drug Effect (Emax) of Vedolizumab as Measured by Percent Inhibition of the Act-1 Marker [ Time Frame: Days 1, 2, 3, 4, 8, 15, 29, 43, 57, 71, 85, 86, 87, 89, 92, 99, 113, 127, 141, 155, 169, 183, 197, 211, 225, 239, and 253 ] [ Designated as safety issue: No ]

    The target of vedolizumab is α4β7 integrin, a receptor found on inflammatory immune cells that guides these inflammatory cells to the gut and binds to the Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) on gut endothelial cells. The extent of the α4β7 receptor saturation by vedolizumab was assessed using the Act-1 binding interference assay. Act-1 is a mouse antibody similar to vedolizumab that also binds α4β7 integrin. The assay measures the percent inhibition of the Act-1 due to the presence of vedolizumab binding.

    Emax was calculated on Day 1, Day 85 and based on all available data.


  • Maximum Drug Effect (Emax) as Measured by Inhibition of the MAdCAM-1-Fc Marker [ Time Frame: Days 1, 2, 3, 4, 8, 15, 29, 43, 57, 71, 85, 86, 87, 89, 92, 99, 113, 127, 141, 155, 169, 183, 197, 211, 225, 239, and 253 ] [ Designated as safety issue: No ]

    The target of vedolizumab is α4β7 integrin, a receptor found on inflammatory immune cells that guides these inflammatory cells to the gut and binds to the mucosal addressin cell adhesion molecule-1 (MAdCAM-1) on gut endothelial cells. The extent of the α4β7 receptor saturation by vedolizumab was assessed using the MAdCAM-1-Fc binding interference assay. MAdCAM-1-Fc is a fusion of human MAdCAM-1 with parts of a mouse monoclonal antibody. The assay measures the percent inhibition of the MAdCAM-1-Fc binding to α4β7 integrin due to the presence of vedolizumab binding.

    Emax was calculated on Day 1, Day 85, and based on all available data.


  • Area Under the Drug Effect Time Curve [AUEC(0-last)] as Measured by Inhibition of the ACT-1 Marker [ Time Frame: Days 1, 2, 3, 4, 8, 15, 29, 43, 57, 71, 85, 86, 87, 89, 92, 99, 113, 127, 141, 155, 169, 183, 197, 211, 225, 239, and 253 ] [ Designated as safety issue: No ]
    AUEC (0-last) is the area under the drug effect-time curve until the last available time point. Mean percent inhibition over time [AUEC(0-last)] was determined for the Act-1 marker. Act-1 is a mouse antibody similar to vedolizumab that also binds α4β7 integrin.

  • Area Under the Drug Effect Time Curve [AUEC(0-last)] as Measured by Inhibition of the MAdCAM-1-Fc Marker [ Time Frame: Days 1, 2, 3, 4, 8, 15, 29, 43, 57, 71, 85, 86, 87, 89, 92, 99, 113, 127, 141, 155, 169, 183, 197, 211, 225, 239, and 253 ] [ Designated as safety issue: No ]
    AUEC (0-last) is the area under the drug effect-time curve until the last available time point. Mean percent inhibition over time [AUEC(0-last)] was determined for the MAdCAM-1-Fc marker. MAdCAM-1-Fc is a fusion of human MAdCAM-1 with parts of a mouse monoclonal antibody.


Enrollment: 47
Study Start Date: May 2007
Study Completion Date: September 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Vedolizumab-matching placebo, intravenous (IV), infusion on Days 1, 15, 29 and 85.
Drug: Placebo
Placebo intravenous infusion
Experimental: Vedolizumab 2 mg/kg
Vedolizumab, 2 mg/kg, IV infusion on Days 1, 15, 29 and 85.
Drug: Vedolizumab
Vedolizumab for intravenous infusion
Other Names:
  • Entyvio
  • MLN0002
  • MLN02
  • LDP-02
Experimental: Vedolizumab 6 mg/kg
Vedolizumab 6 mg/kg, IV infusion on Days 1, 15, 29 and 85.
Drug: Vedolizumab
Vedolizumab for intravenous infusion
Other Names:
  • Entyvio
  • MLN0002
  • MLN02
  • LDP-02
Experimental: Vedolizumab 10 mg/kg
Vedolizumab 10 mg/kg, IV infusion on Days 1, 15, 29 and 85.
Drug: Vedolizumab
Vedolizumab for intravenous infusion
Other Names:
  • Entyvio
  • MLN0002
  • MLN02
  • LDP-02

Detailed Description:

At the end of the study, eligible participants could enroll and receive treatment and follow-up in Study C13004 (NCT00619489). Participants who did not proceed into Study C13004 were followed by telephone contact at 6-month intervals for 2 years after the last administration of study treatment to collect reports of adverse events, including colectomy, severe infections [including progressive multifocal leukoencephalopathy (PML)], and dysplasia/cancer.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Each patient must meet all of the following inclusion criteria to be enrolled in the study.

  • Males or non-pregnant, non-lactating females voluntarily able to give informed consent
  • All patients must agree to use 2 effective forms of contraception from screening to the end of the study
  • Negative surveillance colonoscopy within the last 6 months if indicated by standard clinical practice guidelines
  • Confirmed and active ulcerative colitis (UC)

    • Partial Mayo Score 1 - 7
    • Disease involvement extending proximal to the rectum
  • May be receiving a therapeutic dose of conventional therapies for UC as defined by the protocol

Exclusion Criteria:

Patients meeting any of the following exclusion criteria are not to be enrolled in the study.

  • Patients who require ulcerative colitis (UC) surgical intervention or for whom surgical intervention is anticipated during the study
  • Patients who fail to meet laboratory values as specified in the protocol or have a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist during the screening period
  • Low-grade dysplasia, high-grade dysplasia, dysplasia-associated lesion or mass, or colorectal cancer
  • Treatment with cyclosporine, FK506 (tacrolimus) or infliximab within 60 days prior to study
  • Patients receiving any of the following within 14-days prior to the study: antibiotics for treatment of irritable bowel syndrome, heparin or warfarin, narcotics, tube feeding, defined formula diets or parenteral alimentation
  • Colostomy, fistulae or known fixed symptomatic stenosis of the intestine
  • Immunologic or ischemic intestinal condition
  • Toxic megacolon
  • Chronic hepatitis B or C or human immunodeficiency virus (HIV) infection
  • Any vaccinations within 30 days prior to study drug administration
  • History of imaging abnormalities, multiple sclerosis (MS), brain tumor or neurodegenerative disease
  • Significantly impaired liver or renal function
  • Current or recent history of alcohol dependence
  • Current use of illicit drugs
  • Active or recent serious infections or serious underlying disease as specified in protocol
  • Active psychiatric problems that might interfere with compliance to study
  • Previous exposure to MLN0002
  • Participated in an investigational study within 30 days prior to study drug administration or received treatment with an investigational monoclonal antibody within the last 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01177228

Sponsors and Collaborators
Millennium Pharmaceuticals, Inc.
Investigators
Study Director: Medical Monitor Millennium Pharmaceuticals, Inc.
  More Information

No publications provided

Responsible Party: Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01177228     History of Changes
Other Study ID Numbers: C13002, U1111-1156-8540
Study First Received: August 5, 2010
Results First Received: June 19, 2014
Last Updated: June 19, 2014
Health Authority: Canada: Health Canada
Russia: Pharmacological Committee, Ministry of Health

Additional relevant MeSH terms:
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Inflammatory Bowel Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on July 22, 2014